Literature DB >> 9771756

Vaccine-induced cytotoxic T lymphocytes protect against retroviral challenge.

A D Hislop1, M F Good, L Mateo, J Gardner, M H Gatei, R C Daniel, B V Meyers, M F Lavin, A Suhrbier.   

Abstract

The development of prophylactic vaccines against retroviral diseases has been impeded by the lack of obvious immune correlates for protection. Cytotoxic T-lymphocyte (CTL), CD4-lymphocyteS, chemokine and/or antibody responses have all been associated with protection against HIV and AIDS; however, effective and safe vaccination strategies remain elusive. Here we show that vaccination with a minimal ovine CTL peptide epitope identified within gp51 of the retrovirus bovine leukemia virus (BLV), consistently induced peptide-specific CTLs. Only sheep whose CTLs were also capable of recognizing retrovirus-infected cells were fully protected when challenged with BLV. This retrovirus displays limited sequence variation; thus, in the relative absence of confounding CTL escape variants, virus-specific CTLs targeting a single epitope were able to prevent the establishment of a latent retroviral infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9771756     DOI: 10.1038/2690

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  15 in total

1.  Kinetics of the development of protective immunity in mice vaccinated with a live attenuated retrovirus.

Authors:  U Dittmer; B Race; K J Hasenkrug
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Dissemination of bovine leukemia virus-infected cells from a newly infected sheep lymph node.

Authors:  B E Fulton; M Portella; K Radke
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

3.  Cytotoxic T-lymphocyte epitope vaccination protects against human metapneumovirus infection and disease in mice.

Authors:  Karen A Herd; Suresh Mahalingam; Ian M Mackay; Michael Nissen; Theo P Sloots; Robert W Tindle
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

4.  Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8(+) cytotoxic T-cell epitopes.

Authors:  T Woodberry; J Gardner; L Mateo; D Eisen; J Medveczky; I A Ramshaw; S A Thomson; R A Ffrench; S L Elliott; H Firat; F A Lemonnier; A Suhrbier
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

5.  Protection against establishment of retroviral persistence by vaccination with a live attenuated virus.

Authors:  U Dittmer; D M Brooks; K J Hasenkrug
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

6.  Adoptive immunotherapy of feline immunodeficiency virus with autologous ex vivo-stimulated lymphoid cells modulates virus and T-cell subsets in blood.

Authors:  J Norman Flynn; Mauro Pistello; Patrizia Isola; Lucia Zaccaro; Barbara Del Santo; Enrica Ricci; Donatella Matteucci; Mauro Bendinelli
Journal:  Clin Diagn Lab Immunol       Date:  2005-06

7.  gammadelta(+) T-Lp6phocyte cytotoxicity against envelope-expressing target cells is unique to the alymphocytic state of bovine leukemia virus infection in the natural host.

Authors:  P Lundberg; G A Splitter
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

8.  Bovine leukemia virus structural gene vectors are immunogenic and lack pathogenicity in a rabbit model.

Authors:  L Kucerova; V Altanerova; C Altaner; K Boris-Lawrie
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

9.  Longitudinal analysis of feline leukemia virus-specific cytotoxic T lymphocytes: correlation with recovery from infection.

Authors:  J Norman Flynn; Stephen P Dunham; Vivien Watson; Oswald Jarrett
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

10.  How does HTLV-I persist despite a strong cell-mediated immune response?

Authors:  Becca Asquith; Charles R M Bangham
Journal:  Trends Immunol       Date:  2007-11-26       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.